ANI Pharmaceuticals (ANIP) Given a $74.00 Price Target by Cantor Fitzgerald Analysts
Cantor Fitzgerald set a $74.00 target price on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report report published on Tuesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
ANIP has been the topic of several other research reports. BidaskClub downgraded shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, August 1st. Zacks Investment Research downgraded shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 10th. ValuEngine downgraded shares of ANI Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, September 12th. Finally, Canaccord Genuity set a $75.00 price target on shares of ANI Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, August 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. ANI Pharmaceuticals presently has an average rating of Hold and a consensus target price of $71.00.
Shares of NASDAQ:ANIP traded down $1.38 during midday trading on Tuesday, reaching $52.66. 78,559 shares of the company were exchanged, compared to its average volume of 73,741. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.89 and a current ratio of 3.34. ANI Pharmaceuticals has a one year low of $48.40 and a one year high of $74.70. The firm has a market cap of $653.68 million, a price-to-earnings ratio of 14.59 and a beta of 2.64.
Hedge funds have recently bought and sold shares of the stock. Teachers Retirement System of The State of Kentucky increased its stake in ANI Pharmaceuticals by 99.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 2,005 shares of the specialty pharmaceutical company’s stock worth $113,000 after buying an additional 1,000 shares during the period. Bessemer Group Inc. purchased a new position in ANI Pharmaceuticals in the 3rd quarter worth about $138,000. Piedmont Investment Advisors LLC purchased a new position in ANI Pharmaceuticals in the 2nd quarter worth about $140,000. Truvestments Capital LLC purchased a new position in ANI Pharmaceuticals in the 3rd quarter worth about $152,000. Finally, Stifel Financial Corp purchased a new position in ANI Pharmaceuticals in the 1st quarter worth about $215,000. 61.10% of the stock is currently owned by institutional investors.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
See Also: Outstanding Shares
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.